STAAR Surgical (NASDAQ:STAA) Receives $25.29 Consensus Target Price from Brokerages

STAAR Surgical (NASDAQ:STAA) has earned an average recommendation of “Hold” from the ten research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $25.29.

STAA has been the subject of several research analyst reports. William Blair lowered STAAR Surgical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 12th. Stephens restated an “equal weight” rating and issued a $17.00 price target on shares of STAAR Surgical in a research note on Tuesday, March 18th. Stifel Nicolaus lowered their price objective on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, February 12th. Piper Sandler dropped their price objective on STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, February 12th. Finally, StockNews.com downgraded STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday, February 13th.

STAAR Surgical Stock Up 0.3 %

STAA stock opened at $17.77 on Friday. The company has a market cap of $876.51 million, a P/E ratio of -43.34 and a beta of 0.66. STAAR Surgical has a twelve month low of $13.50 and a twelve month high of $52.68. The business’s fifty day moving average is $19.77 and its 200-day moving average is $25.52.

Insiders Place Their Bets

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. purchased 8,221 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were purchased at an average cost of $21.50 per share, for a total transaction of $176,751.50. Following the acquisition, the insider now owns 10,878,007 shares of the company’s stock, valued at approximately $233,877,150.50. This represents a 0.08 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders acquired 1,036,187 shares of company stock worth $17,239,548. Company insiders own 1.00% of the company’s stock.

Institutional Trading of STAAR Surgical

Several hedge funds have recently modified their holdings of STAA. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in STAAR Surgical by 13.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 110,506 shares of the medical instruments supplier’s stock worth $2,684,000 after purchasing an additional 13,075 shares during the period. Voloridge Investment Management LLC boosted its position in shares of STAAR Surgical by 9.4% during the 4th quarter. Voloridge Investment Management LLC now owns 296,256 shares of the medical instruments supplier’s stock worth $7,196,000 after purchasing an additional 25,350 shares in the last quarter. Squarepoint Ops LLC grew its stake in shares of STAAR Surgical by 81.3% in the 4th quarter. Squarepoint Ops LLC now owns 117,074 shares of the medical instruments supplier’s stock valued at $2,844,000 after buying an additional 52,488 shares during the period. Sherbrooke Park Advisers LLC bought a new stake in STAAR Surgical in the 4th quarter valued at about $502,000. Finally, Raiffeisen Bank International AG acquired a new position in STAAR Surgical during the 4th quarter worth approximately $1,926,000. Institutional investors own 96.70% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.